Kinnate Biopharma Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 17

Employees

  • Latest Deal Type
  • M&A

Kinnate Biopharma General Information

Description

Developer of small-molecule kinase inhibitors intended to treat genomically defined cancers. The company operates as a clinical-stage precision oncology company focused on the discovery and design of therapies for difficult-to-treat, genomically defined cancers.

Contact Information

Website
www.kinnate.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 11975 El Camino Real
  • Suite 101
  • San Diego, CA 92130
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 11975 El Camino Real
  • Suite 101
  • San Diego, CA 92130
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kinnate Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 14-Apr-2025 Completed Generating Revenue
6. Merger/Acquisition 03-Apr-2024 Completed Generating Revenue
5. IPO 03-Dec-2020 Completed Clinical Trials - Phase 1
4. Later Stage VC Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 26-Aug-2020 Completed Startup
2. Early Stage VC (Series B) 12-Dec-2019 $74.5M $96.5M Completed Startup
1. Early Stage VC (Series A) 01-Apr-2018 $22M $22M Completed Startup
To view Kinnate Biopharma’s complete valuation and funding history, request access »

Kinnate Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small-molecule kinase inhibitors intended to treat genomically defined cancers. The company operates as a c
Drug Discovery
San Diego, CA
17 As of 2024

San Diego, CA
 

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kinnate Biopharma Competitors (29)

One of Kinnate Biopharma’s 29 competitors is Erasca, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Erasca Formerly VC-backed San Diego, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Bolt Biotherapeutics Formerly VC-backed Redwood City, CA
Accent Therapeutics Venture Capital-Backed Lexington, MA
MaveriX Oncology Venture Capital-Backed Palo Alto, CA
You’re viewing 5 of 29 competitors. Get the full list »

Kinnate Biopharma Patents

Kinnate Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025054260-A1 Inhibitors of mek kinase Inactive 07-Sep-2023
WO-2025024707-A1 Inhibitors of cdk2/4/6 kinase Inactive 26-Jul-2023
WO-2025024726-A1 Inhibitors of cyclin-dependent kinase Inactive 26-Jul-2023
WO-2025024665-A1 Treatment of cancer with a cdk inhibitor Inactive 26-Jul-2023
WO-2024259060-A1 Inhibitors of met kinase Inactive 16-Jun-2023 C07D471/04
To view Kinnate Biopharma’s complete patent history, request access »

Kinnate Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kinnate Biopharma Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Boxer Capital Corporate Venture Capital Minority
Citadel Enterprise Americas Hedge Fund Minority
Eshelman Ventures Venture Capital Minority
Fidelity Management & Research Company Asset Manager Minority
Foresite Capital Growth/Expansion Minority
You’re viewing 5 of 16 investors. Get the full list »

Kinnate Biopharma Investments & Acquisitions (3)

Kinnate Biopharma’s most recent deal was a Merger/Acquisition with Kinnjiu Biopharma for . The deal was made on 17-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Kinnjiu Biopharma 17-Feb-2023 Merger/Acquisition Drug Discovery
Kinnjiu Biopharma 13-May-2021 Early Stage VC Drug Discovery
Kinnjiu Biopharma 13-May-2021 Joint Venture Drug Discovery
To view Kinnate Biopharma’s complete investments and acquisitions history, request access »

Kinnate Biopharma ESG

Risk Overview

Risk Rating

Updated December, 31, 2022

32.08 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,942

Rank

Percentile

Pharmaceuticals

Industry

of 914

Rank

Percentile

Pharmaceuticals

Subindustry

of 436

Rank

Percentile

To view Kinnate Biopharma’s complete esg history, request access »

Kinnate Biopharma FAQs

  • When was Kinnate Biopharma founded?

    Kinnate Biopharma was founded in 2018.

  • Where is Kinnate Biopharma headquartered?

    Kinnate Biopharma is headquartered in San Diego, CA.

  • What is the size of Kinnate Biopharma?

    Kinnate Biopharma has 17 total employees.

  • What industry is Kinnate Biopharma in?

    Kinnate Biopharma’s primary industry is Drug Discovery.

  • Is Kinnate Biopharma a private or public company?

    Kinnate Biopharma is a Private company.

  • What is Kinnate Biopharma’s current revenue?

    The current revenue for Kinnate Biopharma is .

  • How much funding has Kinnate Biopharma raised over time?

    Kinnate Biopharma has raised $434M.

  • Who are Kinnate Biopharma’s investors?

    Boxer Capital, Citadel Enterprise Americas, Eshelman Ventures, Fidelity Management & Research Company, and Foresite Capital are 5 of 16 investors who have invested in Kinnate Biopharma.

  • Who are Kinnate Biopharma’s competitors?

    Erasca, Kite Pharma, Bolt Biotherapeutics, Accent Therapeutics, and MaveriX Oncology are some of the 29 competitors of Kinnate Biopharma.

  • When was Kinnate Biopharma acquired?

    Kinnate Biopharma was acquired on 14-Apr-2025.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process